BioStock: Spago Nanomedical progresses towards clinical phase with Tumorad

Just before mid-year, Lund-based Spago Nanomedical announced that the company raised 58.4 MSEK in the completed capital round. The proceeds give the company the resources to maintain the pace in its two projects - SpagoPix in cancer diagnostics and Tumorad, in which it is developing a new radionuclide cancer treatment. BioStock reached out to CEO Mats Hansen for comments on recent events and what awaits in the coming six months.

Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se:


This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Source: Cision

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.